| Blood biomarkers |
Lung cancer
histological types |
Verification methods |
Sensitivity and specificity of biomarkers |
Blood biomarkers in other disease |
Reference |
| KLKB1 |
ADC |
Western blot |
- |
- |
[14] |
| SAA |
ADC, SQLC, SCLC |
Western blot, ELISA, Immunohistochemistry, In vivo assay, MRM |
- |
Pancreatic, ovarian, renal and colorectal cancer |
[17,18,85-88] |
| HP-β chain |
ADC, SQLC, SCLC |
Western blot, ELISA |
Sensitivity : 82.6%
Specificity : 63.2% |
Oral, breast, liver, ovarian pancreatic colorectal and bladder cancer |
[20-24] |
| C9 |
SQLC, SCLC |
Western blot, protein arrays, Hybrid AAL lectin ELISA |
Sensitivity : 53%
Specificity : 89% |
Cervical, gastric, colorectal and breast cancer |
[27,89-92] |
| IGFBP-2 and anti-IGFBP-2 autoantibody |
ADC, SQLC |
ELISA, Immunohistochemistry |
Sensitivity : 85.7%
Specificity : 57.5% |
glioma, colorectal, prostate, ovarian and breast cancer |
[29-34] |
| PRX1 |
ADC, SQLC, SCLC |
2-DE screening, Western blot |
- |
- |
[42] |
| CD105 |
NSCLC |
ELISA |
- |
Prostate, breast, colorectal and liver cancers |
[48-52,93] |
| Pgrmc1 |
ADC, SQLC |
Western blot, Immunohistochemistry, In vitro assay |
- |
ovarian, breast cancer |
[56,59] |
| ProGRP |
SCLC |
ARCHITECT ProGRP assay |
Sensitivity : 86.5%
Specificity : 95% |
chronic renal failure |
[64,94] |
| Ciz1 |
ADC, SQLC, SCLC |
Western blot, Immunohistochemistry, In vitro and In vivo assays |
Sensitivity : 95%
Specificity : 74% |
- |
[69] |
| MMP1 |
All |
ELISA, Immunohistochemistry |
- |
colorectal, esophageal, pancreatic, gastric, breast cancer and malignant melanoma |
[72-77] |
| uPAR |
NSCLC |
Three time-resolved fluoroimmunoassays (TR-FIA) |
- |
Colorectal, prostate, ovarian cancer and myeloma |
[83,95-98] |
|
